InvestorsHub Logo
Followers 49
Posts 4480
Boards Moderated 0
Alias Born 03/20/2012

Re: ignatiusrielly35 post# 47229

Monday, 10/14/2019 5:23:42 PM

Monday, October 14, 2019 5:23:42 PM

Post# of 48316
From filing;

If approved by its shareholders, this transaction will provide OncoSec with funding to complete its two ongoing clinical trials of TAVO in combination with Merck's KEYTRUDA®, including its pivotal trial (KEYNOTE-695) in checkpoint-refractory metastatic melanoma and its ongoing clinical trial (KEYNOTE-890) in chemo-refractory metastatic triple negative breast cancer. OncoSec anticipates filing for accelerated approval in the U.S. following the completion of its KEYNOTE-695 trial in 2020.



If approved